StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) company profile

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2024, quý kết thúc ngày Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

About Vaccinex

Pharmaceutical Preparations, SIC 2834

Vaccinex, Inc. is a clinical-stage biotechnology company that discovers and develops targeted biotherapies to address serious conditions with unmet medical needs, particularly neurodegenerative diseases, cancer, and autoimmune disorders. The company's lead product candidate is pepinemab, an antibody designed to block semaphorin 4D signaling for the treatment of Alzheimer's disease as well as head and neck, pancreatic, and breast cancers. In addition, Vaccinex utilizes its proprietary ActivMAb human antibody discovery platform to generate monoclonal antibodies targeting complex multipass membrane proteins, yielding candidates such as VX5 for autoimmune indications. The company collaborates with third-party researchers and pharmaceutical partners who evaluate its pipeline candidates in clinical trials or use its discovery platform under licensing and research agreements.

The company conducts its operations in the United States and maintains its corporate headquarters and principal executive offices in Rochester, New York. Its business activities primarily involve clinical trials and research collaborations conducted across domestic locations.

Summary of the business section of Vaccinex's latest annual report, written by StockData.

Company profile

Company

Legal name
Vaccinex, Inc.
Headquarters
Rochester, NY
Address
1895 Mount Hope Ave 14620
Phone
(585) 271-2700
Employees
23, Dec 31, 2024
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Rochester, New York

Stock & identifiers

Ticker
VCNX
Exchange
OTC
IPO date
Aug 10, 2018
Shares outstanding
3M, Apr 11, 2025
Public float
$5.58M, Jun 30, 2024
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-14 reverse, Feb 20, 2024; 1-for-15 reverse, Sep 26, 2023
SEC CIK
1205922
CUSIP
918640301
ISIN
US9186403013
FIGI
BBG00469NFK4
Share class FIGI
BBG00469NFM2
EIN
16-1603202

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Maurice ZaudererPresident and CEO, Director301,548
Albert FriedbergDirector1,070,387

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 10, 2018
Offer price
$12.00
Securities offered
3,333,334
Gross proceeds
$40.00M
Exchange
Nasdaq
First trading day
Aug 9, 2018
First-day close
$11.38-5.2%
Lock-up ends (est.)
Feb 5, 2019

“The initial public offering price is $12.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2024, we had 23 full-time employees and 4 part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?